Anthralin: how does it act and are there more favourable derivatives?

Area of Science:

• Dermatology
• Pharmacology
• Molecular Biology

Background:

• Anthralin is a highly effective and safe treatment for psoriasis.
• Understanding anthralin's mechanism of action is crucial for developing improved therapies.
• Anthralin impacts keratinocytes and leukocytes, key cells in psoriasis pathogenesis.

Purpose of the Study:

• To elucidate the mode of action of anthralin.
• To identify and synthesize novel anthralin derivatives with enhanced antiproliferative and reduced toxicity profiles.
• To evaluate the therapeutic potential of these new derivatives for psoriasis.

Main Methods:

• In vitro and in vivo studies on human keratinocytes and psoriatic epidermis.
• Time-lapse microscopy to observe keratinocyte mitosis.
• Messenger RNA (mRNA) expression analysis for keratin 6.
• Inhibition assays for lymphocyte transformation and reactive oxygen species release from leukocytes.
• High-performance liquid chromatography (HPLC) to assess metabolic pathways.
• Testing of twelve novel hydrophilic anthralin derivatives.

Main Results:

• Anthralin prolonged keratinocyte prophase and suppressed keratin 6 mRNA expression in vivo.
• Anthralin inhibited lymphocyte transformation and reactive oxygen species release from leukocytes in vitro.
• Protein kinase C was identified as a mediator of anthralin's effects.
• Novel anthralin derivatives with lacton rings exhibited superior antiproliferative effects and comparable or lower cytotoxicity than anthralin.
• These derivatives did not act as pro-drugs, metabolizing independently of anthralin.

Conclusions:

• Anthralin's therapeutic effects are mediated by protein kinase C.
• Novel anthralin derivatives, particularly those with lacton rings, demonstrate enhanced efficacy and safety.
• These findings suggest promising new candidates for topical psoriasis therapy with improved properties over anthralin.